Global Medical REIT (XRN) AI Stock Analysis

• Market Cap: $493.80M
• Dividend Yield: 10.01%
• Average Volume (3M): 124.93K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.59
• Revenue Growth: 2.73%
• EPS Growth: -131.16%
• Country: US
• Employees: 26
• Sector: Real Estate
• Sector Strength: 53
• Industry: REIT - Industrial
• EPS (TTM): -0.55
• Shares Outstanding: 13,234,830
• 10 Day Avg. Volume: 151,735
• 30 Day Avg. Volume: 124,931
• PEG Ratio: 0.00
• Price to Book (P/B): 0.92
• Price to Sales (P/S): 2.90
• P/FCF Ratio: -57.89
• Enterprise Value/Market Cap: 2.22
• Enterprise Value/Revenue: 6.92
• Enterprise Value/Gross Profit: 147.90
• Enterprise Value/Ebitda: 11.67
• 1Y Price Target: $42.00
• Price Target Upside: 22.34% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): -0.3
• Revenue Forecast (FY): $152.90M

• Rating: 49 Neutral
• Price Target: $34.00 ▼(-0.96% Downside)
• Action: Reiterated Date: 03/13/26
• Date: Action: Reiterated 03/13/26

The score is held back primarily by weaker financial quality (2025 net loss, higher leverage, and frequently negative free cash flow) and bearish technical momentum. These are partly offset by a very high dividend yield and a more constructive earnings-call outlook featuring 2026 core FFO guidance and improved debt maturity runway, though with notable macro and execution risks.

Positive Factors

Steady operating cash flow

Consistent operating cash flow of roughly $70–77M provides a durable cash base for a REIT, supporting recurring dividend distributions, routine capital needs, and the ability to fund asset management activities without relying solely on capital markets in the near term.

Strong same-store asset performance

Same-store cash NOI growth of 5.4% and very high occupancy (~96%) indicate resilient demand and effective property operations. That level of asset-level performance underpins sustainable rental income and reduces downside from localized vacancies over the medium term.

Extended debt runway and improving leverage metrics

Eliminating near-term maturities and reducing net debt/adjusted EBITDA to 6.2x materially lowers refinancing risk and gives management time to execute dispositions and capital recycling, improving capital structure resilience and strategic optionality over the next several years.

Negative Factors

Elevated leverage and shrinking equity

Rising leverage and declining equity weaken balance sheet flexibility, increasing sensitivity to interest rate moves and earnings volatility. Higher leverage constrains acquisition capacity, raises refinancing exposure, and amplifies downside risk if property cash flows underperform.

Frequent negative free cash flow

Repeated free cash flow deficits signal that operating cash generation is being consumed by capex, development, or other uses. Persistent negative FCF forces reliance on external financing or asset sales to sustain dividends and growth, increasing dilution and execution risk over time.

Sector headwinds and tenant credit risk

A structurally weaker medical-office demand outlook with modest rent growth expectations, combined with specific tenant bankruptcy exposure, heightens vacancy and collections risk. This undercuts revenue predictability and raises the complexity of redeploying capital into higher-return uses.

Global Medical REIT Business Overview & Revenue Model

Company Description

Global Medical REIT, Inc. engages in the acquisition of purpose-built healthcare facilities and the leasing of those properties to healthcare systems and physician groups. The company was founded on March 18, 2011 and is headquartered in Bethesda, MD.

How the Company Makes Money

Global Medical REIT primarily makes money by acquiring healthcare real estate and leasing those properties to tenants under lease agreements. Its core revenue stream is rental income (base rent) paid by healthcare providers and operators that occupy its buildings. Like many healthcare-focused REITs, its leases may include contractual rent escalations (periodic increases) and can also shift certain property-level operating expenses (e.g., taxes, insurance, and maintenance) to tenants depending on lease structure; when applicable, these arrangements support net operating income stability. The company may also generate revenue related to leasing activity (such as reimbursements or recoveries of property operating costs where permitted by leases). In addition to property-level cash flows, overall earnings are influenced by portfolio occupancy, tenant credit performance, lease renewals, acquisition activity (adding new rent-producing properties), and the spread between property yields and the company’s cost of capital. If the company sells properties, it can realize gains or losses on dispositions, though this is generally not the primary recurring income source for a REIT. Specific tenant or partnership details: null.

Global Medical REIT Financial Statement Overview

Summary

Mixed fundamentals: revenue has grown over time, and operating cash flow has been steady and sizable, but profitability is volatile (net loss in 2025), leverage is elevated and rising (debt-to-equity ~1.30), and free cash flow has been negative in most recent years—limiting financial flexibility.

Income Statement

Revenue has grown over the period (from $93.5M in 2020 to $161.0M in 2025), with a strong rebound in 2025 after a slightly down 2024. Profitability, however, has weakened: net income swung to a loss in 2025 (-$5.8M) after being positive in 2021–2024, and net margins have been inconsistent (negative in 2020 and 2025). Operating profitability remains decent (EBIT margin ~16.8% in 2025), but the earnings volatility reduces confidence in the quality and stability of reported profits.

Balance Sheet

Leverage is meaningful and has crept up, with debt-to-equity rising from ~0.93 (2021) to ~1.30 (2025). Equity has also declined since 2022 (from ~$633.0M to ~$509.8M), while total assets have been roughly flat, suggesting limited balance sheet strengthening. Returns on equity are modest in good years and turned negative in 2025, highlighting sensitivity to earnings swings and the added risk that comes with higher leverage.

Cash Flow

Operating cash flow is relatively steady and healthy in size (about $70–77M in 2022–2025), which is a key support for a REIT profile. The weakness is free cash flow volatility and frequent deficits: free cash flow was negative in 2021, 2022, 2024, and 2025 (including -$8.1M in 2025), with only 2023 showing strong positive free cash flow. The pattern suggests recurring capital needs or reinvestment requirements that pressure cash available after spending.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	161.03M	138.41M	140.93M	137.17M	115.80M
Gross Profit	10.32M	109.16M	112.85M	111.98M	100.32M
EBITDA	83.91M	91.47M	111.64M	102.89M	85.35M
Net Income	-5.84M	6.63M	20.61M	19.14M	17.62M
Balance Sheet
Total Assets	1.24B	1.26B	1.27B	1.39B	1.26B
Cash, Cash Equivalents and Short-Term Investments	12.45M	6.82M	1.28M	4.02M	7.21M
Total Debt	663.74M	653.59M	624.19M	704.65M	579.86M
Total Liabilities	712.40M	700.57M	661.89M	744.20M	625.91M
Stockholders Equity	509.77M	534.13M	583.58M	632.98M	622.78M
Cash Flow
Free Cash Flow	-8.08M	-25.07M	58.39M	-79.66M	-132.69M
Operating Cash Flow	73.61M	70.05M	68.44M	76.54M	68.97M
Investing Cash Flow	-60.40M	-45.94M	67.62M	-137.25M	-194.66M
Financing Cash Flow	-10.26M	-21.89M	-143.79M	62.41M	127.70M

Global Medical REIT Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 34.33
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XRN, the sentiment is Negative. The current price of 34.33 is below the 20-day moving average (MA) of 35.45, below the 50-day MA of 35.55, and above the 200-day MA of 33.41, indicating a neutral trend. The MACD of -0.38 indicates Positive momentum. The RSI at 43.27 is Neutral, neither overbought nor oversold. The STOCH value of 33.15 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XRN.

Global Medical REIT Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SILA	73 Outperform	$1.30B	38.71	2.44%	6.98%	3.74%	77.82%
CHCT	66 Neutral	$444.01M	86.44	1.16%	12.08%	3.40%	-240.85%
Sector *	65 Neutral	$2.17B	12.19	3.79%	4.94%	3.15%	1.96%
UHT	64 Neutral	$561.37M	30.78	10.87%	7.51%	0.68%	-1.34%
STRW	64 Neutral	$167.23M	21.96	49.30%	4.62%	29.76%	22.76%
DHC	54 Neutral	$1.62B	-13.73	-15.98%	0.80%	4.10%	8.96%
XRN	49 Neutral	$493.80M	―	-1.16%	10.01%	2.73%	-131.16%

Global Medical REIT Corporate Events

Global Medical REIT Expands Equity and Preferred Stock Programs

On March 11, 2026, Chiron Real Estate Inc. filed supplementary charter documents in Maryland to classify an additional 3,000,000 shares as 8.00% Series B Cumulative Redeemable Preferred Stock, lifting its total authorization to 5,300,000 preferred shares, and amended its operating partnership agreement to permit a matching increase in economically equivalent Series B preferred units. The company plans to contribute net proceeds from future preferred stock issuances to its operating partnership, reinforcing the REIT’s capital structure and aligning cash flows between the parent and partnership.

On March 12, 2026, Chiron Real Estate Inc. amended and restated its at-the-market common stock offering program, reflecting its new corporate name and adding Huntington Securities and Raymond James as additional agents, forward sellers and forward purchasers, with about $288 million of common shares remaining available for sale or forward transactions. The company simultaneously launched a new at-the-market program for up to $75 million of Series B preferred stock, expanding its equity-raising flexibility through both spot and forward issuances, which may affect future dilution, leverage and income securities available to investors.

The most recent analyst rating on (XRN) stock is a Hold with a $37.00 price target. To see the full list of analyst forecasts on Global Medical REIT stock, see the XRN Stock Forecast page.

Global Medical REIT Establishes New Uncommitted Senior Note Facility

On March 2, 2026, Chiron Real Estate LP and its guarantor Chiron Real Estate Inc. entered into a Master Note and Guaranty Agreement with NYL Investors LLC and New York Life affiliates, creating an uncommitted senior note facility of up to $150 million in aggregate outstanding principal. The facility allows the operating partnership, subject to purchaser discretion and customary conditions, to issue senior unsecured notes in series with maturities of up to ten years, minimum tranches of $10 million, interest set as a spread over U.S. Treasuries, optional prepayment with a make-whole, and pari passu ranking with its other senior unsecured indebtedness.

This financing arrangement expands Chiron Real Estate LP’s potential access to flexible, long-term unsecured capital without obligating New York Life to fund, which could enhance the partnership’s ability to time the debt markets and manage its liability profile, but also leaves execution risk given the uncommitted nature of the facility and its termination triggers tied to defaults or acceleration events.

The most recent analyst rating on (XRN) stock is a Buy with a $42.00 price target. To see the full list of analyst forecasts on Global Medical REIT stock, see the XRN Stock Forecast page.

Chiron Unveils Rebrand, Dividend Shift and 2026 Strategy

Chiron Real Estate Inc., previously known as Global Medical REIT Inc., has completed a corporate rebrand effective February 23, 2026, including a legal name change for both the company and its operating partnership, new NYSE trading symbols, and the launch of a new corporate website. The healthcare-focused REIT, which invests primarily in medical and hospital properties, ended 2025 with 5.1 million square feet of leasable space, 96.0% occupancy, $119.1 million in annualized cash NOI, and a balance sheet featuring $653.9 million of debt and no maturities due in 2026 or 2027.

On February 25, 2026, Chiron reported a fourth-quarter 2025 net loss attributable to common stockholders of $7.4 million, or $0.55 per diluted share, versus net income a year earlier, but delivered stronger operating metrics, including a 26% year-over-year increase in FFO to $0.97 per share and unit, a 6.4% rise in Core FFO to $1.16, and 5.4% same-property cash NOI growth. Capital moves in the quarter included repurchasing 175,634 common shares for $6.0 million, extending credit facility maturities and eliminating a SOFR spread adjustment, and raising $51.3 million via a public offering of 8.00% Series B preferred stock, while disposing of two facilities for $11.3 million in proceeds after a $6.7 million impairment on a Melbourne, Florida asset.

The company outlined 2026 strategic objectives aimed at driving shareholder returns and optimizing portfolio performance through disciplined capital management and portfolio repositioning, supported by a largely fixed-rate debt profile with a 3.74% weighted average interest rate and new forward-starting swaps to fix Term Loan A tranches from May 2026. It also maintained capital flexibility with a $50 million stock repurchase program, under which only $6.0 million had been used by year-end, an untapped ATM program, and $220 million of available borrowing capacity on its credit facility as of February 24, 2026.

In a notable shift for income-focused investors, Chiron’s board approved a change from quarterly to monthly common dividends beginning with the next payment cycle, while keeping the annualized rate unchanged at $3.00 per share, and declared monthly cash dividends totaling $0.75 per share for April, May, and June 2026. The board also declared regular quarterly cash dividends on the company’s 7.50% Series A and 8.00% Series B cumulative redeemable preferred shares, reinforcing its commitment to returning capital to both common and preferred shareholders.

The company continued to diversify its portfolio with its inaugural active adult investment, committing $7.1 million in January 2026 for a 49% interest in a joint venture to develop a 132-unit luxury active adult community near Minneapolis, Minnesota, supported by a $31.0 million construction loan. This move into active adult residential assets, undertaken alongside a programmatic development partner, signals a broader strategic tilt beyond traditional medical facilities and may offer new growth avenues as demographic trends support demand for age-targeted housing.

Operationally, Chiron faces emerging tenant risk after White Rock Medical Center, LLC, its tenant at an acute-care hospital in Dallas, filed for Chapter 11 bankruptcy on January 20, 2026 following a dispute with a former operator, highlighting the inherent counterparty risks in single-tenant healthcare real estate. While the company emphasized progress in transforming its business over the past eight months and showcased its plan in a new investor presentation posted February 25, 2026, investors will be watching closely how it manages this tenant situation and executes on its rebranding and strategic initiatives under the new Chiron identity.

The most recent analyst rating on (XRN) stock is a Hold with a $38.00 price target. To see the full list of analyst forecasts on Global Medical REIT stock, see the XRN Stock Forecast page.